MedTrace Logo

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

NCT01191177 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-06-22

No results posted yet for this study

Summary

The purpose of this study is to investigate the usefulness of oral fish oil(Lovaza)in normalizing liver function in patients who have parenteral nutrition associated liver disease. The investigators believe that patients who take oral fish oil will normalize liver function faster than those who do not

Conditions

Interventions

DRUG

Lovaza (omega-3-acid ethyl ester)

supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test

DIETARY_SUPPLEMENT

Corn oil

1 gram per kilogram body weight per day, not exceeding 4 grams

Sponsors & Collaborators

Principal Investigators

  • Tom Jaksic, MD, PhD · Children's Hopsital Boston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Days
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01191177 on ClinicalTrials.gov